Background: The 1,2,4-triazole scaffold is a highly versatile heterocycle widely explored in medicinal chemistry due to its broad spectrum of biological activities, including anxiolytic, antifungal, and anticancer effects. Its structural adaptability makes it a valuable framework for central nervous system (CNS) drug design. Methodology: A virtual library of forty structurally diverse 1,2,4-triazole derivatives (S1–S40) was rationally designed. Biological activity prediction was carried out using PASS, while pharmacokinetic properties were assessed via Swiss-ADME and toxicity profiles through ProTox-II. Molecular docking studies were performed against the human synaptic GABAA receptor (PDB ID: 6D6U) using AutoDock Vina in the PyRx platform. Results and Discussion: All compounds complied with Lipinski’s Rule of Five and exhibited high gastrointestinal absorption. Many derivatives showed blood–brain barrier permeability and CYP1A2 inhibition potential. PASS analysis indicated predominant anxiolytic, insulysin inhibitory, antiseborrheic, and neuropeptide Y2 antagonistic activities. Docking results revealed that compounds S11 (−8.7 kcal/mol) and S3 (−8.3 kcal/mol) demonstrated stronger binding affinity than diazepam (−7.7 kcal/mol), forming key interactions with SER, TYR, PHE, HIS, and MET residues. The favorable ADME, toxicity, and docking profiles suggest strong CNS drug-likeness and receptor compatibility. Enhanced binding interactions compared to the standard drug highlight the potential of these derivatives as effective GABAA modulators. Conclusion: The studied 1,2,4-triazole derivatives represent promising lead candidates for anxiolytic drug development, meriting further experimental validation.